JP2010523696A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523696A5
JP2010523696A5 JP2010503205A JP2010503205A JP2010523696A5 JP 2010523696 A5 JP2010523696 A5 JP 2010523696A5 JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010523696 A5 JP2010523696 A5 JP 2010523696A5
Authority
JP
Japan
Prior art keywords
methyl
dose
effective amount
carboplatin
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/059905 external-priority patent/WO2008124822A1/en
Publication of JP2010523696A publication Critical patent/JP2010523696A/ja
Publication of JP2010523696A5 publication Critical patent/JP2010523696A5/ja
Pending legal-status Critical Current

Links

JP2010503205A 2007-04-10 2008-04-10 脳腫瘍を治療する方法 Pending JP2010523696A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91097507P 2007-04-10 2007-04-10
PCT/US2008/059905 WO2008124822A1 (en) 2007-04-10 2008-04-10 Method of treating brain cancer

Publications (2)

Publication Number Publication Date
JP2010523696A JP2010523696A (ja) 2010-07-15
JP2010523696A5 true JP2010523696A5 (enExample) 2011-07-14

Family

ID=39831435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503205A Pending JP2010523696A (ja) 2007-04-10 2008-04-10 脳腫瘍を治療する方法

Country Status (9)

Country Link
US (1) US20100129470A1 (enExample)
EP (1) EP2144504A4 (enExample)
JP (1) JP2010523696A (enExample)
KR (1) KR20100016385A (enExample)
CN (1) CN101742910A (enExample)
AU (1) AU2008236993A1 (enExample)
CA (1) CA2720982A1 (enExample)
NZ (1) NZ580866A (enExample)
WO (1) WO2008124822A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
AU2008236997A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
NZ590913A (en) * 2008-07-11 2012-09-28 Myrexis Inc (2-aminomethylquinazolin-4-yl)-(4-methoxyphenyl)methylamine for treating or ameliorating neoplasm or cancer
US20110224240A1 (en) * 2010-01-11 2011-09-15 Myrexis, Inc. Methods of treating cancer and related diseases
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
NZ631022A (en) * 2013-06-05 2018-05-25 Cytrx Corp Cytotoxic agents for the treatment of cancer
CN105288629B (zh) * 2014-05-28 2021-02-19 北京大学 具有药效叠加作用及毒性分散效应的组合药物
GB2578974B (en) * 2015-04-17 2020-08-19 Univ Holy Ghost Duquesne Cyclopenta[d]pyrimidines as antitubulin and antitumor agents
IL278311B2 (en) * 2018-05-02 2024-02-01 Tel Hashomer Medical Res Infrastructure & Services Ltd Preparations and methods for the treatment of glioblastoma
EP3831412A4 (en) * 2018-07-31 2022-04-27 Daiichi Sankyo Company, Limited TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE
CN116143693B (zh) * 2020-06-24 2026-04-10 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4317399A (en) * 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
US7001926B2 (en) * 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
PL369336A1 (en) * 2001-09-21 2005-04-18 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US7470723B2 (en) * 2003-03-05 2008-12-30 Celgene Corporation Diphenylethylene compounds and uses thereof
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
KR20080014144A (ko) * 2003-08-18 2008-02-13 화이자 프로덕츠 인크. ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
CA2592971A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Method of treating brain cancer
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
US20070249640A1 (en) * 2005-06-16 2007-10-25 Myriad Genetics, Incorporated Pharmaceutical compositions and use thereof
US20070065449A1 (en) * 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
AU2008236997A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
WO2009023876A1 (en) * 2007-08-16 2009-02-19 Myriad Genetics, Inc. Method of treating non-small cell lung cancer

Similar Documents

Publication Publication Date Title
JP2013503174A5 (enExample)
US11224599B2 (en) Therapeutic agents and methods
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
JP2008535902A5 (enExample)
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
CR7693A (es) Terapia de combinacion para enfermedades hiperproliferativas
RU2012111235A (ru) Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
TW201107327A (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
EP3064220A3 (en) Compositions and methods for the treatment of infections and tumors
PH12012500504A1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer
WO2009012096A3 (en) Improved therapeutic methods and compositions comprising chroman ring compounds
WO2009120697A4 (en) Method and compositions for treatment of cancer
US11702443B2 (en) Therapeutic agents and methods
JP2015514756A5 (enExample)
JP2009506054A5 (enExample)
JPWO2015115310A1 (ja) がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤
JP2013520499A5 (enExample)
Iqubal et al. A technical note on emerging combination approach involved in the onconanotherapeutics
HUP0301247A2 (hu) Antitumor terápia disztamicin származékokkal
RU2015119802A (ru) Комбинированная терапия рака
Hu et al. Current status of CPT and its analogues in the treatment of malignancies
PH12013502048B1 (en) Therapeutic treatment